Belantamab mafodotin - Wikipedia
WEBBelantamab mafodotin, sold under the brand name Blenrep, is a monoclonal antibody conjugated with a cytotoxic agent for the treatment of relapsed and refractory multiple myeloma. [2] [5] [6] [3]
FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for …
WEBBLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and anti-CD38 antibody.
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review ...
WEBJan 21, 2021 · The first drug in its class, belantamab mafodotin-blmf (brand name Blenrep) is a novel therapeutic agent recently approved by the FDA to treat relapsed or treatment-refractory multiple myeloma. Belamaf is an immunoconjugate anti-B-cell maturation antigen with high specificity for multiple myeloma cells [ 7 ] .
FDA granted accelerated approval to belantamab mafodotin-blmf …
WEBOn August 5, 2020, the Food and Drug Administration granted accelerated approval to belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline) for adult patients with relapsed or refractory multiple...
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · Blenrep (belantamab mafodotin) plus PomDex showed statistically significant and clinically meaningful progression-free survival compared to bortezomib plus PomDex; Consistent efficacy results observed for Blenrep combinations in …
Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate …
WEBFeb 1, 2022 · Belantamab mafodotin-blmf (Blenrep) is a first-in-class antibody-drug conjugate directed against B-cell maturation antigen (BCMA) that obtained U.S. Food and Drug Administration accelerated approval in August 2020 for patients with multiply relapsed/refractory MM.
“Real-life” data of the efficacy and safety of belantamab ... - Nature
WEBDec 7, 2021 · Belantamab mafodotin (belamaf® or blenrep®) is the first in class member of the ADCs in MM that utilizes a humanized monoclonal antibody which targets B cell maturation antigen (BCMA) [6,7,8].
FDA approves GSK's Blenrep for advanced multiple myeloma
WEBSep 15, 2024 · Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein...
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell …
WEBOct 10, 2021 · GSK2857916 (belantamab mafodotin, BLENREP) is a BCMA-targeting antibody–drug conjugate approved for the treatment of relapsed/refractory multiple myeloma. We report that GSK2857916 induces immunogenic cell death in BCMA-expressing cancer cells and promotes dendritic cell activation in vitro and in vivo.
Belantamab Mafodotin: First Approval | Drugs - Springer
WEBSep 16, 2020 · Belantamab mafodotin (BLENREP™, belantamab mafodotin-blmf) is a first-in-class humanised IgG1 monoclonal antibody-drug conjugate (ADC) developed by GlaxoSmithKline (GSK) for the treatment of multiple myeloma and other haematological malignancies [1].